With Setara, the team behind Actio opens its second act

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 30 Oct, 10:30 UTC

The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.

science

Sources

• T2With Setara, the team behind Actio opens its second actBioPharma Dive / Healthcare Dive / MedTech Dive30 Oct, 10:30